Drugs / DLE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02506998 | Aug 2013 → Jan 2015 | allergic disease | National Polytechnic Institute, Mexico | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DLE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02506998 ↗ |
| Modality | Peptide | “DLE, a peptide-based immunomodulator” PMID 37417619 ↗ Jul 2023 |
| Route | Oral | “DLE was administered orally” PMID 37417619 ↗ Jul 2023 |